Compare NAAS & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAAS | NEPH |
|---|---|---|
| Founded | 2019 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 40.1M |
| IPO Year | 2017 | 2004 |
| Metric | NAAS | NEPH |
|---|---|---|
| Price | $3.14 | $3.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 23.7K | 6.6K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $377.00 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $1.80 | $2.66 |
| 52 Week High | $4.54 | $6.42 |
| Indicator | NAAS | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 49.79 |
| Support Level | $2.85 | $3.19 |
| Resistance Level | $3.25 | $3.78 |
| Average True Range (ATR) | 0.25 | 0.24 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 18.19 | 44.74 |
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.